Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2005

View Archived Issues

MF-101: a safer alternative for hormonal therapy

In vivo studies confirm the anti-HSV activity of a cream formulation of resveratrol

Anti-HBV activity of ellagic acid

Vestipitant shows anxiolytic-like profile in rodent and primate behavioral models

DPI-221 shows potential as an agent for overactive bladder and urinary incontinence

Scientists describe advantages of using two antibodies in PAGRIT

Aripiprazole reported effective in preventing relapse of patients with bipolar disorder

Scientists find link between novel locus and left main coronary artery disease risk

Phase II study discontinued for vicriviroc in treatment-naive HIV patients

Cellegy completes enrollment in phase III HIV prevention study of Savvy

Approval of muraglitazar may require new trials

Enrollment begins in phase I Chemophase study

Biolex to create commercial line for Kringle's NK4 protein

Update on ongoing Avian flu research

Positive phase III results for GSK drug from Flamel collaboration

Dacogen under review in U.S. and Europe for MDS

Positive phase I findings for Fentanyl Taifun

Chromos Molecular Systems to acquire Targeted Molecules

Accelerated approval for Arranon

FDA extends Exubera review period

Erbitux sBLA accepted for filing, granted priority review

Cerepro MAA accepted for review

Schering-Plough seeks Japanese approval of Temodal

Escitalopram reported to improve kleptomania, PMDD and depression

MD-1100 demonstrates gastrointestinal activity in healthy volunteers

Novel antiinfective agents emerge from sanofi-aventis R&D

New therapeutic agents claimed for metabolic disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...